Evaluation of combination protocols of the chemotherapeutic agent FX-9 with azacitidine, dichloroacetic acid, doxorubicin or carboplatin on prostate carcinoma cell lines.

por Franziska Weiner, Jan Torben Schille, Jens Ingo Hein, Xiao-Feng Wu, Matthias Beller, Christian Junghanß, Hugo Murua Escobar, Ingo Nolte
Publicado 2021